Jed A. Latkin
2017
In 2017, Jed A. Latkin earned a total compensation of $814.4K as Chief Executive Officer, Chief Operating Officer and Chief Financial Officer at Navidea Biopharmaceuticals, a 150% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $366,653 |
---|---|
Option Awards | $125,833 |
Salary | $316,458 |
Other | $5,429 |
Total | $814,373 |
Latkin received $366.7K in non-equity incentive plan, accounting for 45% of the total pay in 2017.
Latkin also received $125.8K in option awards, $316.5K in salary and $5.4K in other compensation.
Rankings
In 2017, Jed A. Latkin's compensation ranked 9,945th out of 14,666 executives tracked by ExecPay. In other words, Latkin earned more than 32.2% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 9,945 | 32nd |
Manufacturing | 3,849 | 33rd |
Chemicals And Allied Products | 1,340 | 35th |
Drugs | 1,086 | 37th |
In Vitro and In Vivo Diagnostic Substances | 41 | 43rd |
Latkin's colleagues
We found two more compensation records of executives who worked with Jed A. Latkin at Navidea Biopharmaceuticals in 2017.
News
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019